A detailed history of Avoro Capital Advisors LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Avoro Capital Advisors LLC holds 4,196,661 shares of ASND stock, worth $531 Million. This represents 7.81% of its overall portfolio holdings.

Number of Shares
4,196,661
Previous 3,966,666 5.8%
Holding current value
$531 Million
Previous $600 Million 4.55%
% of portfolio
7.81%
Previous 7.23%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$121.07 - $153.67 $27.8 Million - $35.3 Million
229,995 Added 5.8%
4,196,661 $572 Million
Q1 2024

May 15, 2024

BUY
$123.45 - $159.4 $26.1 Million - $33.7 Million
211,111 Added 5.62%
3,966,666 $600 Million
Q4 2023

Feb 14, 2024

BUY
$86.1 - $127.36 $7.37 Million - $10.9 Million
85,555 Added 2.33%
3,755,555 $473 Million
Q3 2023

Nov 14, 2023

BUY
$86.5 - $103.97 $7.74 Million - $9.3 Million
89,445 Added 2.5%
3,670,000 $344 Million
Q2 2023

Aug 14, 2023

BUY
$69.96 - $97.84 $17.9 Million - $25 Million
255,555 Added 7.69%
3,580,555 $320 Million
Q1 2023

May 15, 2023

BUY
$104.9 - $126.78 $23.6 Million - $28.5 Million
225,000 Added 7.26%
3,325,000 $357 Million
Q4 2022

Feb 14, 2023

BUY
$99.42 - $131.97 $24.9 Million - $33 Million
250,000 Added 8.77%
3,100,000 $379 Million
Q3 2022

Nov 14, 2022

BUY
$84.03 - $110.23 $48.3 Million - $63.4 Million
575,000 Added 25.27%
2,850,000 $294 Million
Q2 2022

Aug 15, 2022

BUY
$78.08 - $117.61 $5.86 Million - $8.82 Million
75,000 Added 3.41%
2,275,000 $211 Million
Q1 2022

May 16, 2022

BUY
$102.18 - $135.75 $20.4 Million - $27.2 Million
200,000 Added 10.0%
2,200,000 $258 Million
Q4 2021

Feb 14, 2022

BUY
$127.1 - $169.66 $2.54 Million - $3.39 Million
20,000 Added 1.01%
2,000,000 $269 Million
Q3 2021

Nov 15, 2021

BUY
$112.67 - $176.92 $9.01 Million - $14.2 Million
80,000 Added 4.21%
1,980,000 $316 Million
Q2 2021

Aug 16, 2021

BUY
$121.62 - $145.29 $231 Million - $276 Million
1,900,000 New
1,900,000 $250 Million
Q1 2021

May 17, 2021

SELL
$124.92 - $173.33 $225 Million - $312 Million
-1,800,000 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$134.29 - $154.32 $6.71 Million - $7.72 Million
50,000 Added 2.86%
1,800,000 $278 Million
Q2 2020

Aug 14, 2020

SELL
$110.87 - $156.01 $4.1 Million - $5.77 Million
-37,000 Reduced 2.07%
1,750,000 $259 Million
Q1 2020

May 15, 2020

SELL
$97.01 - $145.11 $7.57 Million - $11.3 Million
-78,000 Reduced 4.18%
1,787,000 $201 Million
Q4 2019

Feb 14, 2020

SELL
$91.45 - $139.12 $9.6 Million - $14.6 Million
-105,000 Reduced 5.33%
1,865,000 $259 Million
Q2 2019

Aug 14, 2019

BUY
$107.11 - $132.09 $18.7 Million - $23.1 Million
175,000 Added 9.75%
1,970,000 $227 Million
Q1 2019

May 15, 2019

SELL
$62.15 - $129.99 $11.5 Million - $24 Million
-185,000 Reduced 9.34%
1,795,000 $211 Million
Q4 2018

Feb 14, 2019

BUY
$55.16 - $69.67 $919,186 - $1.16 Million
16,664 Added 0.85%
1,980,000 $124 Million
Q3 2018

Nov 14, 2018

SELL
$63.77 - $76.28 $6.38 Million - $7.63 Million
-100,000 Reduced 4.85%
1,963,336 $139 Million
Q1 2018

May 15, 2018

BUY
$38.98 - $68.04 $14.9 Million - $26 Million
382,312 Added 22.74%
2,063,336 $135 Million
Q4 2017

Feb 14, 2018

BUY
$31.98 - $40.38 $1.44 Million - $1.81 Million
44,900 Added 2.74%
1,681,024 $67.3 Million
Q3 2017

Nov 14, 2017

BUY
$26.89 - $37.1 $44 Million - $60.7 Million
1,636,124
1,636,124 $59.3 Million

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.07B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Avoro Capital Advisors LLC Portfolio

Follow Avoro Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Avoro Capital Advisors LLC with notifications on news.